Weight loss in women taking flibanserin for hypoactive sexual desire disorder (HSDD): Insights into potential mechanisms

Articles

Weight loss in women taking flibanserin for hypoactive sexual desire disorder (HSDD): Insights into potential mechanismsIntroduction: Flibanserin, a multifunctional serotonin receptor agonist and antagonist, is currently approved in the United States and Canada for the treatment of acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women. A post hoc analysis of HSDD clinical trial…

Effect of flibanserin treatment on body weight in premenopausal and postmenopausal women with hypoactive sexual desire disorder: a post hoc analysis

Articles

Effect of flibanserin treatment on body weight in premenopausal and postmenopausal women with hypoactive sexual desire disorder: a post hoc analysisBackground: Flibanserin, a 5-HT 1A  agonist and 5-HT 2A  antagonist, is indicated for the treatment of acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women. This post hoc analysis evaluated the effect of flibanserin…

Evaluation of flibanserin safety: Comparison with other serotonergic medications

Articles

Evaluation of flibanserin safety: Comparison with other serotonergic medicationsIntroduction: Flibanserin, a multifunctional serotonin agonist and antagonist, is approved by the U.S. Food and Drug Administration (FDA) for treatment of acquired, generalized hypoactive sexual desire disorder in premenopausal women. During the FDA’s review of flibanserin, concerns were raised about the risks of hypotension, syncope, and sedation-related…

Safety of flibanserin in women treated with antidepressants: a randomized, placebo-controlled study

Articles

Safety of flibanserin in women treated with antidepressants: a randomized, placebo-controlled studyBackground: Depression is often associated with sexual dysfunction, and pharmacologic treatment for hypoactive sexual desire disorder can be considered in women receiving treatment for depression. Aim: To evaluate the safety of flibanserin in women treated for depression with selective serotonin reuptake inhibitors or serotonin…

Multifunctional pharmacology of flibanserin: possible mechanism of therapeutic action in hypoactive sexual desire disorder

Articles

Multifunctional pharmacology of flibanserin: possible mechanism of therapeutic action in hypoactive sexual desire disorderIntroduction: Flibanserin is a novel pharmacologic agent in late-stage clinical testing for hypoactive sexual desire disorder (HSDD) in premenopausal women. Aim: The aim of this article is to review the hypothetical mechanism of action of flibanserin in HSDD. Methods: A literature review…

Flibanserin for hypoactive sexual desire disorder: an open-label safety study

Articles

Flibanserin for hypoactive sexual desire disorder: an open-label safety studyBackground: To evaluate the safety of flibanserin in premenopausal and naturally postmenopausal women with hypoactive sexual desire disorder (HSDD) in an open-label extension (OLE) study. Aim: To examine the safety and tolerability of flibanserin 100 mg once daily at bedtime in the treatment of premenopausal and…

Continued efficacy and safety of flibanserin in premenopausal women with Hypoactive Sexual Desire Disorder (HSDD): results from a randomized withdrawal trial

Articles

Continued efficacy and safety of flibanserin in premenopausal women with Hypoactive Sexual Desire Disorder (HSDD): results from a randomized withdrawal trialIntroduction: Flibanserin is a 5-HT(1A) agonist/5-HT(2A) antagonist that has been shown to increase sexual desire and reduce distress in premenopausal women with Hypoactive Sexual Desire Disorder (HSDD). Aim: To assess the efficacy and safety of…

Open-label extension study of flibanserin in women with hypoactive sexual desire disorder

Articles

Open-label extension study of flibanserin in women with hypoactive sexual desire disorderIntroduction: Hypoactive Sexual Desire Disorder (HSDD) is a common form of Female Sexual Dysfunction characterized by low sexual desire that causes distress or interpersonal difficulty. Aim: This 52-week open-label extension study aimed to assess the safety and tolerability of flibanserin, a postsynaptic 5-HT(1A) agonist/5-HT(2A)…

Treatment of Hypoactive Sexual Desire Disorder in Premenopausal Women: Efficacy of Flibanserin in the VIOLET Study.

Articles

Treatment of Hypoactive Sexual Desire Disorder in Premenopausal Women: Efficacy of Flibanserin in the VIOLET Study.Introduction: Hypoactive sexual desire disorder (HSDD) is the most common form of female sexual dysfunction and is characterized by low sexual desire that causes distress. Aim: The aim of this study was to assess the efficacy and safety of flibanserin,…